Abstract
Amyloid (A beta) deposition remains a hallmark in the pathology of Alzheimer disease (AD). Important drug discovery efforts dedicated to the inhibition of the polymerization process leading to amyloid neurotoxicity are pursued by academic groups and the pharmaceutical industry as a potential preventive treatment for AD. The aim of this review is to up-date current knowledge on the amyloid aggregation process and the various available peptidic and non-peptidic A beta aggregation inhibitors.
Keywords: Aggregation Inhibitors, Alzheimers Disease, Anti-inflammatory agents, Antioxidants, Neurotrophic, Ab Aggregation Inhibition, AMYLOID AGGREGATION INHIBITORS, Thyrotrophin releasing hormone (TRH), Melatonin, Hexadecyl-N-methylpiperidinium (HMP) bromide
Mini-Reviews in Medicinal Chemistry
Title: beta-Amyloid Aggregation Inhibitors for the Treatment of Alzheimer Disease Dream or Reality?
Volume: 1 Issue: 2
Author(s): Patrice Talaga
Affiliation:
Keywords: Aggregation Inhibitors, Alzheimers Disease, Anti-inflammatory agents, Antioxidants, Neurotrophic, Ab Aggregation Inhibition, AMYLOID AGGREGATION INHIBITORS, Thyrotrophin releasing hormone (TRH), Melatonin, Hexadecyl-N-methylpiperidinium (HMP) bromide
Abstract: Amyloid (A beta) deposition remains a hallmark in the pathology of Alzheimer disease (AD). Important drug discovery efforts dedicated to the inhibition of the polymerization process leading to amyloid neurotoxicity are pursued by academic groups and the pharmaceutical industry as a potential preventive treatment for AD. The aim of this review is to up-date current knowledge on the amyloid aggregation process and the various available peptidic and non-peptidic A beta aggregation inhibitors.
Export Options
About this article
Cite this article as:
Talaga Patrice, beta-Amyloid Aggregation Inhibitors for the Treatment of Alzheimer Disease Dream or Reality?, Mini-Reviews in Medicinal Chemistry 2001; 1 (2) . https://dx.doi.org/10.2174/1389557013407098
DOI https://dx.doi.org/10.2174/1389557013407098 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Caregiver Involvement in Sexual Risk Reduction with Substance Using Juvenile Delinquents: Overview and Preliminary Outcomes of a Randomized Trial
Adolescent Psychiatry Nanovesicle Formulation Enhances Anti-inflammatory Property and Safe Use of Piroxicam
Pharmaceutical Nanotechnology The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents
Current Topics in Medicinal Chemistry Recent Insights into Notch Signaling in Embryonal Rhabdomyosarcoma
Current Drug Targets Identification of New Drug Targets and Biomarkers Related to Obesity and Eating Disorders: an Approach Based on Reward Deficit and Addiction
Current Pharmaceutical Design Cyclodextrins: More than Pharmaceutical Excipients
Mini-Reviews in Medicinal Chemistry Intracranial Aneurysms in Sickle Cell Disease
Current Neurovascular Research Dampening the Progression of Dementia
Current Neurovascular Research Overview on the Tricks of HIV Tat to Hit the Blood Brain Barrier
Current HIV Research Human Kallikrein 6 Cerebrospinal Levels are Elevated in Multiple Sclerosis
Current Drug Discovery Technologies Physiological Roles of Neuronal Nicotinic Receptors Subtypes: New Insights on the Nicotinic Modulation of Neurotransmitter Release, Synaptic Transmission and Plasticity
Current Topics in Medicinal Chemistry Cognition in First-Episode Psychosis: From Phenomenology to Intervention
Current Psychiatry Reviews Effects of Cocaine on Maternal Behavior and Neurochemistry
Current Neuropharmacology Stress, Depression and Hippocampal Apoptosis
CNS & Neurological Disorders - Drug Targets 3,4-Dihydroxyphenylacetaldehyde: A Potential Target for Neuroprotective Therapy in Parkinsons Disease
Current Drug Targets - CNS & Neurological Disorders Insulin and the Future Treatment of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets The Potential of Serratiopetidase and Lumbrokinase for the Degradation of Prion Peptide 106-126 - an <i>In Vitro</i> and <i>In Silico</i> Perspective
CNS & Neurological Disorders - Drug Targets Self Managing Heart Failure in Remote Australia - Translating Concepts into Clinical Practice
Current Cardiology Reviews Editorial (Hot Topic: Fragile X Families: A Lifespan Perspective)
Current Psychiatry Reviews Phytochemistry and Pharmacological Update on Tetraterpenoids
The Natural Products Journal